Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria

被引:44
|
作者
Nakayama, Hirokazu [1 ]
Usuki, Kensuke [2 ]
Echizen, Hirotoshi [3 ]
Ogawa, Ryuichi [3 ]
Orii, Takao [1 ]
机构
[1] NTT Med Ctr Tokyo, Dept Pharm, Shinagawa Ku, 5-9-22 Higashi Gotanda, Tokyo 1418625, Japan
[2] NTT Med Ctr Tokyo, Dept Hematol, Shinagawa Ku, 5-9-22 Higashi Gotanda, Tokyo 1418625, Japan
[3] Meiji Pharmaceut Univ, Dept Pharmacotherapy, 2-522-1 Noshio, Kiyose, Tokyo 2048588, Japan
关键词
eculizumab; dosing interval; breakthrough hemolysis; paroxysmal nocturnal hemoglobinuria; COMPLEMENT INHIBITOR ECULIZUMAB; TERM SAFETY;
D O I
10.1248/bpb.b15-00703
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Eculizumab given bi-weekly is widely recommended for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). We undertook a retrospective analysis on the medical records of 763 dosings of 14 PNH patients to investigate whether a threshold would exist in dosing intervals associated with breakthrough hemolysis. We identified 12 events of breakthrough hemolysis in 4 patients. Multivariate logistic regression and receiver operating characteristics (ROC) analysis revealed a significant association between increased risk of breakthrough hemolysis and prolonged dosing intervals of 17 days or more and concomitant inflammation: odds ratios (OR) and 95% confidence intervals (CIs) were 1.6 (1.3-2.0, p<0.01) and 5.5 (1.3-22.8, p=0.02), respectively. ROC analysis showed that the best cut-off dosing interval discriminating breakthrough hemolysis was 16.5 days. We consider that eculizumab dosing intervals longer than 17 days may be associated with an increased risk for developing breakthrough hemolysis in patients with PNH.
引用
收藏
页码:285 / 288
页数:4
相关论文
共 50 条
  • [21] Transfusion-dependent breakthrough hemolysis accompanied by an acute Budd-Chiari Syndrome (BCS) in a pregnant patient with Paroxysmal Nocturnal Hemoglobinuria (PNH) on eculizumab
    Alsara, M.
    Alashkar, F.
    Baum, J.
    Saner, F.
    Koeninger, A.
    Duehrsen, U.
    Roeth, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 157 - 157
  • [22] Complement Biomarkers for Tracking Breakthrough Hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated with Last-Generation Complement Inhibitors
    Marano, Luana
    Ricci, Patrizia
    Frieri, Camilla
    Urciuoli, Eleonora
    Sanseverino, Ada
    Cacace, Fabiana
    Manfra, Ilenia
    De Santis, Giovanna
    Vitiello, Selenia
    Marotta, Serena
    Risitano, Antonio
    BLOOD, 2022, 140 : 5797 - 5798
  • [23] Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones
    Mei, Matthew
    Gupta, Rohan
    O'Donnell, Margaret
    Al Malki, Monzr M.
    Aldoss, Ibrahim
    Ali, Haris
    Farol, Leonardo
    Snyder, David
    Forman, Stephen J.
    Nakamura, Ryotaro
    Khaled, Samer
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (05) : E183 - E185
  • [24] Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization
    Hill, Anita
    Rother, Russell P.
    Arnold, Louise
    Kelly, Richard
    Cullen, Matthew J.
    Richards, Stephen J.
    Hillmen, Peter
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (04): : 567 - 573
  • [25] A spontaneous reduction of clone size in paroxysmal nocturnal haemoglobinuria patients treated with eculizumab for greater than 12 months
    Kelly, R. J.
    Richards, S. J.
    Arnold, L. M.
    Valters, G.
    Cullen, M.
    Hill, A.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 12 - 12
  • [26] Eculizumab, a C5 complement-blocking antibody, abolishes hemolysis and reduces transfusion dependency in patients with paroxysmal nocturnal hemoglobinuria (PNH)
    Rother, RP
    Hall, C
    Marsh, J
    Elebute, D
    Mojcik, CF
    Rollins, SA
    Richards, S
    Cullen, M
    Hillmen, P
    MOLECULAR IMMUNOLOGY, 2003, 40 (2-4) : 197 - 197
  • [27] C3-Mediated Extravascular Hemolysis as Additional Mechanism of Disease in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated by the Complent Inhibitor Eculizumab
    Risitano, Antonio M.
    Marando, Ludovica
    Ranaldi, Danilo
    Seneca, Elisa
    Serio, Bianca
    Gianfaldoni, Giacomo
    Antonioli, Elisabetta
    Milano, Filippo
    Amendola, Angela
    Boschetti, Carla
    Barcellini, Wilma
    Di Bona, Eros
    Carella, Angelo Michele
    Barbano, Filippo
    Bonfigli, Silvana
    Capalbo, Silvana
    Fabbiano, Francesco
    Pulini, Stefano
    Marino, Antonio
    Pietrogrande, Francesco
    Iuliano, Franco
    Rodeghiero, Francesco
    Zanella, Alberto
    Iori, Annapaola
    Notaro, Rosario
    Luzzatto, Lucio
    Rotoli, Bruno
    BLOOD, 2008, 112 (11) : 184 - 185
  • [28] Association Between Elevated Hemolysis at Diagnosis and Early Mortality and Risk of Thrombosis In Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients with Cytopenia
    Kim, Jin Seok
    Lee, Jong Wook
    Yoon, Sung-Soo
    Lee, Je-Hwan
    Jo, Deog-Yeon
    Jang, Jun-Ho
    Kim, Yeo-Kyung
    Chung, Jooseop
    Sohn, Sang Kyun
    BLOOD, 2010, 116 (21) : 1722 - 1722
  • [29] Significant disease burden in paroxysmal nocturnal hemoglobinuria patients with lower levels of hemolysis, mild anemia and minimal transfusion: Clinical improvement with eculizumab therapy.
    Bessler, Monica
    Schrezenmeier, Hubert
    Maciejewski, Jaroslaw P.
    Hill, Anita
    Rollins, Scott A.
    Young, Neal S.
    Luzzatto, Lucio
    BLOOD, 2007, 110 (11) : 257A - 258A
  • [30] Direct Antiglobulin Test, Ferritin and GPI-Negative Cell Populations in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) during Eculizumab Therapy: Extravascular Hemolysis Unmasked by Efficient Eculizumab-Mediated Inhibition of Intravascular Hemolysis
    Hoechsmann, Britta
    Rojewski, Markus
    Flegel, Willy A.
    Schrezenmeier, Hubert
    BLOOD, 2008, 112 (11) : 1180 - 1180